Bristol-Myers Squibb (BMY) –
-
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
-
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
-
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascul
-
Bristol-Myers Squibb's (BMY) Abecma Approved in EU
-
Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myel
-
Bristol-Myers Squibb (BMY) Announces CheckMate -9DW Trial of Opdivo Plus Yervoy Met Primary Endpoint
-
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocel
-
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign
-
Form 8-K BRISTOL MYERS SQUIBB CO For: Mar 13
-
Form PRE 14A BRISTOL MYERS SQUIBB CO For: May 07
-
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
-
Form 8-K BRISTOL MYERS SQUIBB CO For: Mar 18
-
Bristol-Myers Squibb (BMY) Completes Acquisition of Karuna Therapeutics (KRTX)
-
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
-
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
-
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
-
Bristol-Myers Squibb (BMY): FDA Advisers Vote 8:3 in Favor of Abecma as Earlier Treatment for a Type of Blood Cancer
-
Bristol-Myers Squibb (BMY) FDA Approves Breyanzi for Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (
-
Karuna Therapeutics (KRTX) Discloses Termination of HSR Waiting Period for Bristol-Myers (BMY) Deal
-
US FDA staff raises concerns over data from J&J, Bristol's CAR-T therapies
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Lenkowsky Adam
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Plenge Robert M
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Poole Ahn Amanda
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Hirawat Samit
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Holzer Phil M
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Hoch Lynelle
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Gallman Cari
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: BOERNER CHRISTOPHER S.
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Shanahan Karin
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Meyers Gregory Scott
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Hickey Benjamin
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Elkins David V
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Caforio Giovanni
-
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
-
Societe Generale Downgrades Bristol-Myers Squibb Co. (BMY) to Hold, 'ranks at the bottom of SG’s global peer group'
-
Bristol-Myers Squibb (BMY) Announces FDA Approval of Opdivo in Combination with Cisplatin and Gemcitabine
-
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Ca
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $56 at Jefferies
-
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 01 Filed by: Hickey Benjamin
-
Form 3 BRISTOL MYERS SQUIBB CO For: Feb 26 Filed by: Hickey Benjamin
-
Bristol-Myers Squibb (BMY) Declares $0.60 Quarterly Dividend; 4.7% Yield
-
Bristol Myers Squibb Announces Dividend
-
Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
-
Tapestry, Inc. Appoints Kevin Hourican and David Elkins to Board of Directors
-
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
-
Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference
-
Bristol-Myers Squibb (BMY) Completes Acquisition of RayzeBio (RYZB)
-
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Back to BMY Stock Lookup